Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Bookmark
  • News

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

By Emily Hayes

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Cancer Gynecology & Urology
Bookmark
  • Analysis

Glenmark Spins Out Innovation With New US Base

By Anju Ghangurde
Glenmark’s innovation business will now be housed in a spin-out arm, based in the US, where the Indian parent believes the ecosystem is more conducive to cutting-edge R&D. The new structure could also potentially provide new opportunities to unlock value for the parent company.
Commercial Strategy
Bookmark
  • News

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns

By Sue Sutter

Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.

Advisory Committees Drug Review
Bookmark
  • Interviews

Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

By John Davis

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.

 

Neurology Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By